May 26, 2006 11:58 ET

DUSA Pharmaceuticals to Present at the Friedman Billings Ramsey 2006 Growth Conference

WILMINGTON, MASSACHUSETTS--(CCNMatthews - May 26, 2006) - DUSA Pharmaceuticals, Inc. (NASDAQ NMS:DUSA) announced today that Geoff Shulman, Chairman & CEO and Bob Doman, President & COO, will present at the Friedman Billings Ramsey 2006 Growth Conference. The presentation is scheduled for 11:15 a.m. EDT on Thursday, June 1, 2006 at the Grand Hyatt New York Hotel in New York, NY.

The presentation will be available as a live audio and visual webcast on the Company's website at www.dusapharma.com or at www.wsw.com/webcast/fbr15/dusa/. A replay of this presentation will be available on these websites for 60 days.

About DUSA

DUSA Pharmaceuticals, Inc. is an integrated dermatology specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of pre-cancerous actini keratoses, and is being developed for the treatment of acne and photodamage. DUSA's other dermatology products include Nicomide®, and the AVAR® line, resulting from its recent merger with Sirius Laboratories, Inc. These products target patients with acne and rosacea. DUSA is also developing certain internal indications of Levulan PDT. DUSA is based in Wilmington, MA.

Contact Information

  • DUSA Pharmaceuticals, Inc.
    Shari Lovell
    Director, Shareholder Services
    (416) 363-5059
    (416) 363-6602 (FAX)